Drug intelligence / Profile preview

DW16012

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW16012 is an investigational drug evaluated in clinical trials for the treatment of acute bronchitis. It has been studied as a comparator arm in phase 3 clinical trials alongside other agents such as DW1601 and DW16011. While detailed composition and mechanism of action information for DW16012 specifically is not available from public sources, it appears to be related to or derived from the same development program as these other agents, which include combinations with Pelargonium sidoides extract and dihydrocodeine compounds. The primary developer associated with these studies is Daewon Pharmaceutical.

Brand names: DW16012DW-16012DW 16012
Other names: DW16012DW-16012DW 16012

Beyond the preview

Go deeper on DW16012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW16012.

Explore the full profile